We recruited 260 patients with EGFR mutation–positive NSCLC and acquired resistance to EGFR-TKIs from 29 institutions in Japan between 4 November 2014 and 13 March 2015 (Table 1). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.